Finding a Niche for Celgene’s Otezla

Brian Orelli

More Articles

Comments (0)

Celgene‘s (NASDAQ: CELG  ) new psoriatic arthritis drug Otezla isn’t going to beat the current offerings from AbbVie (NYSE: ABBV  ) , Johnson Johnson (NYSE: JNJ  ) , and Amgen (NASDAQ: AMGN  ) on an efficacy basis.

But it doesn’t have too. Unlike Humira, Remicade, Enbrel, and the rest of the injected or infused biologics, Otezla is taken orally, giving Celgene a distinct advantage over AbbVie, Johnson Johnson, and Amgen.

That doesn’t mean Otezla will be an instant blockbuster though. As Fool contributor Brian Orelli and health-care bureau chief Max Macaluso discuss in the video below, Celgene needs to find a sweat spot, positioning Otezla between oral generics and the biologics doctors are comfortable prescribing.